Share Email Print

Proceedings Paper

Active immunotherapy of Walker-256 carcinosarcoma by tumor-infiltrating lymphocytes associated with photodynamic therapy
Author(s): Vasile F. Dima; Virgil V. Vasiliu; Dezideriu Laky; Paul Ionescu; Stefan V. Dima
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Experiments were performed on five batches of Wistar inbred rats with Walker-256 carcinosarcoma receiving as sole treatment photodynamic therapy (PDT), tumor-infiltrating lymphocytes (TIL), or associated therapy (PDT + TIL - A; PDT + TIL - B). The control batch (HBSS) consisted of animals with untreated Walker-256 tumors. The results were as follows: the sole treatment (PDT, TIL) gave survival rates between 41.4 and 52.9%, the cure rates ranging from 13.8 to 38.2%. The `combined' therapy in multiple doses increased significantly (92.8%) the survival rate of tumor bearing rats as well as the highest incidence of complete tumor regression (82.1%). Cell-mediated immunity test values in batches III and IV exposed to multiple doses of PDT + TIL showed higher values as compared to the values noticed in batches I - II and the control batch V, performed at 10 and 21 days post-treatment. Summing up, this work demonstrates that `combined' photodynamic therapy with immunotherapy with TIL stimulates cell-mediated antitumoral activity, increases survival rates, and reduces incidence of Walker-256 carcinosarcoma in the rat model.

Paper Details

Date Published: 12 January 1995
PDF: 12 pages
Proc. SPIE 2325, Photodynamic Therapy of Cancer II, (12 January 1995); doi: 10.1117/12.199148
Show Author Affiliations
Vasile F. Dima, Cantacuzino Institute (Romania)
Virgil V. Vasiliu, Institute of Atomic Physics (Romania)
Dezideriu Laky, Victor Babes Institute (Romania)
Paul Ionescu, Military Central Hospital (Romania)
Stefan V. Dima, Cantacuzino Institute (Romania)

Published in SPIE Proceedings Vol. 2325:
Photodynamic Therapy of Cancer II
Daniel Brault; Giulio Jori; Johan Moan; Benjamin Ehrenberg, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?